Pancreatic Cancer Research

ResearcherSecond Affiliated Hospital of Xi'an Jiaotong UniversityNo recent work listed

Zhengliang Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9800-3140; OpenAlex author ID A5026149938. Sources: OpenAlex.

Their work

Papers
7 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
9
Papers, trials and grants by year

2015: 2 papers · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper

Papers 7

  1. [Retracted] MicroRNA‑153 is a prognostic marker and inhibits cell migration and invasion by targeting SNAI1 in human pancreatic ductal adenocarcinoma. Last author DOI 10.3892/or.2022.8444↗
  2. SLC1A5 Prefers to Play as an Accomplice Rather Than an Opponent in Pancreatic Adenocarcinoma. Co-author DOI 10.3389/fcell.2022.800925↗
  3. Bioinformatic mining and validation of the effects of ferroptosis regulators on the prognosis and progression of pancreatic adenocarcinoma. First author DOI 10.1016/j.gene.2021.145804↗
  4. M6A Regulatory Genes Play an Important Role in the Prognosis, Progression and Immune Microenvironment of Pancreatic Adenocarcinoma. First author DOI 10.1080/07357907.2020.1834576↗
  5. miR-135b-5p Promotes migration, invasion and EMT of pancreatic cancer cells by targeting NR3C2. Co-author DOI 10.1016/j.biopha.2017.11.074↗
  6. miR-186 and 326 predict the prognosis of pancreatic ductal adenocarcinoma and affect the proliferation and migration of cancer cells. Co-author DOI 10.1371/journal.pone.0118814↗
  7. MicroRNA-153 is a prognostic marker and inhibits cell migration and invasion by targeting SNAI1 in human pancreatic ductal adenocarcinoma. Last author DOI 10.3892/or.2015.4051↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Honghong Pei · 5 shared papers, 2015–2023 · strength 0.56
  2. Fangshi Xu · 3 shared papers, 2021–2022 · strength 0.47
  3. Zhenghai Bai · 4 shared papers, 2015–2023 · strength 0.42
  4. Ling Bai · 3 shared papers, 2015–2021 · strength 0.37
  5. Xiaobo Wang · 3 shared papers, 2015–2023 · strength 0.34
  6. Honghong Pei · 2 shared papers, 2021–2022 · strength 0.32
  7. Bincheng Ren · 1 shared paper, 2022 · strength 0.16
  8. Hai Wang · 1 shared paper, 2022 · strength 0.16
  9. Fei Miao · 1 shared paper, 2015 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.